Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kimberly Cheng"'
Autor:
Kimberly Cheng
Publikováno v:
German Studies Review. 46:17-34
Autor:
Kimberly Cheng
Publikováno v:
German Studies Review. 46:130-132
Publikováno v:
American Journal of Gastroenterology. 117:e461-e463
Publikováno v:
American Journal of Gastroenterology. 117:e468-e469
Autor:
Kimberly Cheng, Saikiran Kilaru
Publikováno v:
American Journal of Gastroenterology. 117:e1900-e1901
Autor:
Kimberly Cheng, Adam S. Faye
Publikováno v:
World Journal of Gastroenterology
Patients with inflammatory bowel disease (IBD) are at an increased risk for venous thromboembolism (VTE). VTE events carry significant morbidity and mortality, and have been associated with worse outcomes in patients with IBD. Studies have suggested
Autor:
Jemily Malvar, Sonata Jodele, Hisham Abdel-Azim, Yueh-Yun Chi, Etan Orgel, Amy Sacapano, Kimberly Cheng, Rusha Bhandari, Paibel Aguayo-Hiraldo, Gregory Wallace, Shahab Asgharzadeh
Publikováno v:
Transplantation and cellular therapy. 27(12)
Vitamin D is essential for bone health and has immunomodulatory properties. Most pediatric patients are vitamin D insufficient (30 ng/mL) before hematopoietic stem cell transplantation (HSCT). Standard supplementation strategies fail to achieve vitam
Autor:
Hunter J. Summers, Lauren A. Michel, Kimberly Cheng, Kieran P. McNulty, Daniel J. Peppe, Samuel Muteti, Alan L. Deino, Heather B. Vineyard, Thomas Lehmann
Publikováno v:
Geological Society of America Abstracts with Programs.
Autor:
Garrett Lawlor, Daniel E. Freedberg, John W. Blackett, Benjamin Lebwohl, Kimberly Cheng, Jianhua Li, Kenneth W. Hung, Anna Sophia Mckenney, Adam S. Faye, Adam R. Pont
Publikováno v:
Inflamm Bowel Dis
Background Despite increased risk of venous thromboembolism (VTE) among hospitalized patients with inflammatory bowel disease (IBD), pharmacologic prophylaxis rates remain low. We sought to understand the reasons for this by assessing factors associa
Autor:
Dionysios Neofytos, Yao-Ting Huang, Nina Cohen, Genovefa A. Papanicolaou, Miguel Perales, Juliet N. Barker, Sergio Giralt, Ann A. Jakubowski, Kimberly Cheng
Publikováno v:
Clinical Infectious Diseases. 61:S652-S661
Background. The use of mold-active azoles for antifungal prophylaxis after allogeneic stem cell transplantation (SCT) is hindered by adverse events and drug–drug interactions. Higher doses of echinocandins administered intermittently may be an alte